Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.13%69.381.0%$932.59m
AMGNAmgen Inc.
0.31%173.680.8%$658.54m
BIIBBiogen Inc.
0.04%287.000.9%$536.80m
CELGCelgene Corporation
0.16%119.631.0%$480.75m
REGNRegeneron Pharmaceuticals, Inc.
-0.44%369.971.9%$346.85m
ALXNAlexion Pharmaceuticals, Inc.
1.22%131.482.0%$303.24m
TSROTESARO, Inc.
0.44%191.1015.3%$199.85m
INCYIncyte Corporation
0.05%122.422.3%$170.20m
ILMNIllumina, Inc.
0.56%163.053.9%$148.84m
VRTXVertex Pharmaceuticals Incorporated
0.17%86.702.6%$140.31m
CLVSClovis Oncology, Inc.
0.33%63.2016.4%$132.81m
EXELExelixis, Inc.
-1.73%22.715.5%$129.20m
AAgilent Technologies, Inc.
0.34%51.531.7%$117.68m
ACADACADIA Pharmaceuticals Inc.
0.00%39.2019.0%$93.83m
BMRNBioMarin Pharmaceutical Inc.
-0.12%90.144.0%$89.88m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.